ArticleAlcohol, clinical & experimental research2026
The NKCC1 Antagonist Bumetanide, Administered After Prenatal Alcohol Exposure, Mitigates Ethanol-Induced Aberrance in Tangential Migration of GABAergic Interneurons in Mouse Medial Prefrontal Cortex.
Article in Alcohol, clinical & experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPrenatal ethanol (alcohol) exposure (PreEE) results in abnormal tangential migration of medial ganglionic eminence (MGE)-derived GABAergic interneurons (GINs) in the embryonic mouse medial prefrontal cortex (mPFC); later in life, this is associated with impaired behavioral flexibility commonly seen in fetal alcohol spectrum disorders (FASD). The PreEE-induced abnormal tangential migration involves, in part, ethanol potentiating GABA
methodsNKCC1-like immunofluorescence was assessed following immunohistochemical processing of 30-μm cryosections derived from embryonic day (E)14.5 wild-type mouse brains. Nkx2.1Cre-Ai14 mice were used to genetically label MGE-derived GINs. Pregnant dams were fed 5% ethanol (w/w) from E13.5 to E16.5, followed by bumetanide treatment (320 mg/kg liquid diet) from E17.5 until postnatal day (P) 0 (birth). Forty-micron cryosections from brains of progeny were collected at P0, and the density as well as spatial distribution of tdTomato-fluorescent (Nkx2.1+) GINs in the mPFC quantified.
resultsWithin the timeframe of PreEE, the NKCC1 protein is expressed ubiquitously in the embryonic mouse brain, including the dorsomedial telencephalon, the precursor to mPFC. PreEE increased the overall density of Nkx2.1+ GINs and accelerated their dorsal-to-ventral dispersion across the developing mPFC. Post-PreEE treatment with the NKCC1 antagonist bumetanide diminished these effects, reducing dorsal accumulation while preserving the baseline population of GINs.
conclusionsThese results indicate that blocking the NKCC1 chloride importer bumetanide can mitigate PreEE-induced interneuronopathy when administered after PreEE, implicating NKCC1 as a potential pharmacological target for post-PreEE therapeutic intervention of FASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.